Category: Biotechnology
Global Biotechnology
-
Cardiac Biomarkers
... CAGR of 7.3% over the analysis period 2024-2030. Troponins (T & I), one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$11.2 Billion by the end of ... Read More
-
Drug Discovery Informatics
... at a CAGR of 9.6% over the analysis period 2024-2030. Software Component, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$3.4 Billion by the end of ... Read More
-
Q-TOF Mass Spectrometry
... at a CAGR of 7.8% over the analysis period 2024-2030. Biotechnology, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$593.6 Million by the end of the ... Read More
-
Cell Based Assays
... at a CAGR of 6.7% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$19.1 Billion by the end of the ... Read More
-
Cell Separation Technologies
... at a CAGR of 15.1% over the analysis period 2024-2030. Research Laboratories & Institutes End-Use, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$24.9 Billion by ... Read More
-
Computational Biology
... CAGR of 18.1% over the analysis period 2024-2030. Contract Services, one of the segments analyzed in the report, is expected to record a 19.2% CAGR and reach US$20.1 Billion by the end of the analysis ... Read More
-
Dairy Enzymes
... CAGR of 6.8% over the analysis period 2024-2030. Chymosin, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$442.0 Million by the end of the analysis period. ... Read More
-
Genome Editing / Genome Engineering
... Billion by 2030, growing at a CAGR of 19.8% over the analysis period 2024-2030. CRISPR Technology, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$18.7 Billion ... Read More
-
GMP Cell Banking Services
... 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Mammalian Cell, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$1.5 Billion by the ... Read More
-
Nanomedicine
... 9.7% over the analysis period 2024-2030. Therapeutics Modality, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$442.7 Billion by the end of the analysis period. Growth ... Read More
-
Oligonucleotide Synthesis
... CAGR of 15.6% over the analysis period 2024-2030. Oligonucleotide-Based Drugs, one of the segments analyzed in the report, is expected to record a 17.3% CAGR and reach US$8.6 Billion by the end of the analysis ... Read More
-
Protein Labeling
... CAGR of 6.0% over the analysis period 2024-2030. Kits, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$957.8 Million by the end of the analysis period. ... Read More
-
Protein Purification and Isolation
... 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$10.3 Billion by the end ... Read More
-
Pyrogen Testing
... CAGR of 10.4% over the analysis period 2024-2030. Assays, Kits & Reagents, one of the segments analyzed in the report, is expected to record a 10.9% CAGR and reach US$1.1 Billion by the end of ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Allogeneic Stem Cells
... at a CAGR of 10.9% over the analysis period 2024-2030. Regenerative Therapy, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Up-Regulated Protein
... CAGR of 6.2% over the analysis period 2024-2030. Diagnostic Labs, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$300.9 Million by the end of the analysis ... Read More
-
Intravenous Immunoglobulin (IVIg)
... at a CAGR of 8.5% over the analysis period 2024-2030. IgA, one of the segments analyzed in the report, is expected to record a 10.6% CAGR and reach US$13.7 Billion by the end of the ... Read More
-
Circulating Tumor Cell (CTC) Diagnostics
... Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2024-2030. Detection & Enrichment, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$15.4 ... Read More
-
microRNA (miRNA)
... CAGR of 13.1% over the analysis period 2024-2030. Products, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$411.8 Million by the end of the analysis period. ... Read More
-
COVID-19 Testing
... CAGR of -15.7% over the analysis period 2024-2030. RT-PCR Assay Kits, one of the segments analyzed in the report, is expected to record a -16.5% CAGR and reach US$3.9 Billion by the end of the ... Read More
-
Global Proteomics - Industry Report
... attractive acquisition opportunities • Analyse industry trends • Benchmark their own financial performance Using an exclusive methodology, a quick glance of this Proteomics (Global) report will tell you the companies that have a declining financial ... Read More
-
Tissue Engineering Market Report by Type (Synthetic Scaffold Material, Biologically Derived Scaffold Material, and Others), Application (Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, and Others), End User (Hospitals and Clinics, Ambulatory Facilities), and Region 2025-2033
... The market is driven by the increasing demand for regenerative medicines and TE procedures, rising incidences of fatal road accidents and trauma injuries, the augmenting need for bone implants among patients, continual technological advancements in ... Read More
-
Biochips
... 12.8% over the analysis period 2024-2030. DNA Chip, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$14.7 Billion by the end of the analysis period. Growth ... Read More
-
Gene Amplification Technologies
... at a CAGR of 10.0% over the analysis period 2024-2030. Medical & Pharma, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$6.4 Billion by the end ... Read More
Research Assistance
